Dr. Ben-Menachem previously served as Director of Business Development at Teva Pharmaceutical Industries, where he was responsible for business development efforts leading to partnering and acquisition deals valued at more than $500 million for late stage innovative drug candidates.
KTOV is underfollowed and misunderstood.
As a result, despite spectacular Phase 3 results, the market undervalues KTOV's compound drug.
I enumerate the reasons for the mis-evaluation and suggest a four-year price target of $22.50.
Gamida Cell Reports Positive Top Line Results of International, Multi-Center, Phase I/II Study of NiCord® for Blood Cancers, Demonstrating Rapid and Durable Hematopoietic Recovery
Positive results support the initiation of a Phase III study of NiCord
The stock of Top Image Systems Limited (NASDAQ:TISA) registered a decrease of 14.19% in short interest. TISA’s total short interest was 88,900 shares in December as published by FINRA. Its down 14.19% from 103,600 shares, reported previously. With 23,300 shares average volume, it will take short sellers 4 days to cover their TISA’s short positions. The stock decreased 3.93% or $0.13 on December 4, hitting $3.18.
We signed one contract with a very important US partner for an additional 50 iBar systems which is our largest single order to date. These milestones highlight the escalation of our iBar land-and-expand strategy.